Business Standard

Merck to buy drug developer Pandion Therapeutics for $1.85 billion

The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday

merck
Premium

Shares of Pandion rose 131.6% to a record high of $59.37 before the bell, while Merck shares were up about 1% | Photo: Reuters

Reuters
Merck & Co Inc said on Thursday it would buy drug developer Pandion Therapeutics Inc for about $1.85 billion in cash, expanding its portfolio of drugs that target autoimmune diseases.
 
The $60-per-share deal represents about 134% premium to Pandion's closing price on Wednesday.
 
Shares of Pandion rose 131.6% to a record high of $59.37 before the bell, while Merck shares were up about 1%.
 
Pandion's lead drug candidate, PT101, met its main goals of safety and tolerability last month in an early-stage trial in patients with autoimmune diseases.
 
In November, Merck agreed to buy privately-held VelosBio for $2.75 billion to
Topics : Merck

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in